Bristol Myers faces billion-dollar claim over cancer drug
An ICC panel in New York is hearing a US$1.5 billion claim against US pharmaceuticals group Bristol Myers Squibb over the supply of a cancer therapy drug that was blocked by Chinese regulators.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10